Adjuvant radiotherapy for pathologically advanced prostate cancer improves biochemical recurrence free survival compared to salvage radiotherapy

Table 1 Patient characteristics

		Received adjuvant therapy	Adjuvant candidate and received salvage radiotherapy	P value
Age at RT (median, IQR), mo		60 (54-65)	63 (59-68)	0.2
Follow-up (mo)		53 (19-83)	50 (22-854)	0.1
Time from RP to RT, mo	0-12	43 (93%)	12 (14%)	< 0.001
	> 12-24	3 (7%)	18 (21%)
	> 24-48	0 (0%)	29 (33%)
	> 48	0 (0%)	28 (32%)
Pre-RT PSA	Undetectable	46 (100%)	0 (0%)	< 0.001
	> 0-0.2	0 (0%)	39 (46%)
	> 0.2-1.0	0 (0%)	38 (45%)
	> 1.0	0 (0%)	7 (8%)
Received	No	37 (79%)	67 (77%)	0.8
Peri-RT ADT	Yes	10 (21%)	20 (23%)
Coronary artery disease	No	36 (86%)	64 (84%)	0.8
	Yes	6 (14%)	12 (16%)
Diabetes mellitus, type II	No	37 (88%)	58 (76%)	0.1
	Yes	5 (12%)	18 (24%)
Hypertension	No	19 (45%)	37 (49%)	0.6
	Yes	23 (55%)	39 (51%)
Obesity	No	31 (74%)	51 (67%)	0.4
	Yes	11 (26%)	25 (33%)
Peripheral vascular disease	No	39 (93%)	73 (96%)	0.4
	Yes	3 (7%)	3 (4%)
Smoking history	No	37 (88%)	70 (92%)	0.5
	Yes	5 (12%)	6 (8%)
Pathologic	2-6	9 (20%)	18 (21%)	0.4
Gleason score	7	21 (48%)	48 (57%)
	8-10	14 (32%)	18 (21%)
Pathologic	T1	0 (0%)	0 (0%)	0.08
Tumor stage	T2	11 (25%)	35 (41%)
	T3/T4	33 (75%)	51 (59%)
Positive surgical margin	Absent	12 (25%)	28 (32%)	0.4
	Present	35 (75%)	59 (68%)
Extracapsular extension	Absent	20 (43%)	41 (47%)	0.6
	Present	27 (57%)	46 (53%)
Seminal vesicle invasion	Absent	37 (79%)	80 (92%)	0.03
	Present	10 (21%)	7 (8%)

RP: Radical prostatectomy; RT: Radiotherapy; IQR: Interquartile range; ADT: Androgen deprivation therapy; PSA: Prostate specific antigen.

Table 2 Stepwise cox regression multivariate analysis

		Biochemical recurrence		Overall survival		Bone metastases		Hormonal therapy
		HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Pathologic gleason score	2-6	Referent	0.01	Referent	0.4	Referent	0.3	Referent	0.005
	7	1.2 (0.4-3.1)	0.8		0.7		0.9	1.2 (0.3-4.6)	0.8
	8-10	3.1 (1.2-8.1)	0.02		0.2		0.1	4.9 (1.4-16.7)	0.01
Pre-RT PSA	Undetectable	Referent	< 0.001	Referent	0.8	Referent	0.045	Referent	< 0.001
	> 0.0-0.2	4.1 (1.5 -11.2)	0.005		0.8	3.3 (0.2-54.2)	0.4	2.6 (0.8-9.1)	0.1
	> 0.2-1.0	4.4 (1.6-11.9)	0.003		0.6	0.6 (0.04-8.6)	0.7	1.7 (0.5-5.8)	0.4
	> 1.0	52 (12.9-210)	< 0.001		0.7	39.8 (1.8-868)	0.02	67.8 (13.7-336)	< 0.001
Received peri-RT ADT			0.7		0.2		0.1		0.6
Seminal vesicle invasion		2.2 (0.99-4.8)	0.053		0.9		0.2	2.7 (1.1-6.6)	0.036
Positive surgical margin			0.056		0.08		0.08		0.09
Extracapsular extension			0.3		0.1		0.6		0.6
Pathologic stage	T2	Referent	0.9	Referent	0.1	Referent	0.9	Referent	0.8
	T3/4

RT: Radiotherapy; PSA: Prostate specific antigen; ADT: Androgen deprivation therapy; CI: Confidence interval.